Shares of Genmab A/S (OTCMKTS:GNMSF - Get Free Report) crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $208.09 and traded as high as $215.30. Genmab A/S shares last traded at $212.55, with a volume of 134 shares changing hands.
Genmab A/S Stock Up 1.1%
The company has a 50 day simple moving average of $208.14 and a 200 day simple moving average of $205.76. The company has a market capitalization of $14.20 billion, a price-to-earnings ratio of 12.19 and a beta of 0.91.
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $3.05 EPS for the quarter, topping analysts' consensus estimates of $1.88 by $1.17. The company had revenue of $765.14 million for the quarter, compared to the consensus estimate of $761.09 million. Genmab A/S had a return on equity of 19.23% and a net margin of 35.11%.
Genmab A/S Company Profile
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
